Hansa Biopharma and Medison Pharma announce multiregional commercialization partnership for Hansa’s desensitization treatment for kidney transplant in Central Eastern Europe and Israel
· Imlifidase has potential to become an important new treatment option for highly sensitized kidney patients awaiting a transplant in selected Central Eastern European countries and Israel · Marketing authorization application for desensitization treatment in kidney transplant filed in Israel earlier this year Lund, Sweden and Petach Tikva, Israel December 7, 2021. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, and Medison Pharma, a global pharma company focused on providing access to highly innovative